SI3265459T1 - Amidne spojine kot 5-HT4 receptor agonisti - Google Patents
Amidne spojine kot 5-HT4 receptor agonistiInfo
- Publication number
- SI3265459T1 SI3265459T1 SI201630311T SI201630311T SI3265459T1 SI 3265459 T1 SI3265459 T1 SI 3265459T1 SI 201630311 T SI201630311 T SI 201630311T SI 201630311 T SI201630311 T SI 201630311T SI 3265459 T1 SI3265459 T1 SI 3265459T1
- Authority
- SI
- Slovenia
- Prior art keywords
- receptor agonists
- amide compounds
- amide
- compounds
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN709CH2015 | 2015-02-13 | ||
| EP16711355.4A EP3265459B1 (en) | 2015-02-13 | 2016-01-07 | Amide compounds as 5-ht4 receptor agonists |
| PCT/IN2016/000008 WO2016128990A1 (en) | 2015-02-13 | 2016-01-07 | Amide compounds as 5-ht4 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3265459T1 true SI3265459T1 (sl) | 2019-09-30 |
Family
ID=55588327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201630311T SI3265459T1 (sl) | 2015-02-13 | 2016-01-07 | Amidne spojine kot 5-HT4 receptor agonisti |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9957257B2 (sl) |
| EP (1) | EP3265459B1 (sl) |
| JP (1) | JP6487564B2 (sl) |
| KR (1) | KR101966576B1 (sl) |
| CN (1) | CN107406434B (sl) |
| AU (1) | AU2016217461B2 (sl) |
| BR (1) | BR112017017275A2 (sl) |
| CA (1) | CA2975973C (sl) |
| CY (1) | CY1121898T1 (sl) |
| DK (1) | DK3265459T3 (sl) |
| EA (1) | EA034618B1 (sl) |
| ES (1) | ES2734734T3 (sl) |
| HR (1) | HRP20191179T1 (sl) |
| HU (1) | HUE045667T2 (sl) |
| IL (1) | IL253848B (sl) |
| LT (1) | LT3265459T (sl) |
| MA (1) | MA41633B1 (sl) |
| MD (1) | MD3265459T2 (sl) |
| ME (1) | ME03430B (sl) |
| MX (1) | MX368214B (sl) |
| NZ (1) | NZ734400A (sl) |
| PL (1) | PL3265459T3 (sl) |
| PT (1) | PT3265459T (sl) |
| RS (1) | RS59066B1 (sl) |
| SG (1) | SG11201706501VA (sl) |
| SI (1) | SI3265459T1 (sl) |
| TR (1) | TR201909997T4 (sl) |
| WO (1) | WO2016128990A1 (sl) |
| ZA (1) | ZA201705292B (sl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106831541B (zh) | 2011-11-18 | 2019-09-06 | 赫普泰雅治疗有限公司 | 毒蕈碱性m1受体激动剂 |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| CN110818661B (zh) * | 2019-12-02 | 2021-08-06 | 上海再启生物技术有限公司 | 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1689742B1 (en) | 2003-11-24 | 2010-03-17 | Pfizer, Inc. | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity |
| WO2005092882A1 (en) * | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
| ES2523459T3 (es) | 2005-02-25 | 2014-11-26 | Raqualia Pharma Inc | Derivados de benzisoxazol |
| EP1910340B1 (en) | 2005-07-22 | 2009-11-18 | Pfizer, Inc. | Indazolecarboxamide derivatives as 5ht4 receptor agonists |
| WO2007048643A1 (en) | 2005-10-28 | 2007-05-03 | Glaxo Group Limited | Novel compound |
| GB0525661D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Novel compounds |
| GB0603550D0 (en) | 2006-02-22 | 2006-04-05 | Glaxo Group Ltd | Novel compounds |
| WO2011099305A1 (en) | 2010-02-12 | 2011-08-18 | Raqualia Pharma Inc. | 5-ht4 receptor agonists for the treatment of dementia |
| KR20120123089A (ko) | 2010-02-16 | 2012-11-07 | 화이자 인코포레이티드 | 5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올 |
| BR112014001083B8 (pt) * | 2011-09-19 | 2022-06-14 | Suven Life Sciences Ltd | Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto |
| NZ712369A (en) * | 2013-03-20 | 2016-11-25 | Suven Life Sciences Ltd | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists |
| EP3099675B1 (en) * | 2013-12-16 | 2018-02-14 | Suven Life Sciences Limited | Indazole compounds as 5-ht4 receptor agonists |
-
2016
- 2016-01-07 AU AU2016217461A patent/AU2016217461B2/en not_active Ceased
- 2016-01-07 SI SI201630311T patent/SI3265459T1/sl unknown
- 2016-01-07 MD MDE20180052T patent/MD3265459T2/ro not_active IP Right Cessation
- 2016-01-07 MA MA41633A patent/MA41633B1/fr unknown
- 2016-01-07 US US15/549,663 patent/US9957257B2/en active Active
- 2016-01-07 HU HUE16711355A patent/HUE045667T2/hu unknown
- 2016-01-07 SG SG11201706501VA patent/SG11201706501VA/en unknown
- 2016-01-07 WO PCT/IN2016/000008 patent/WO2016128990A1/en active Application Filing
- 2016-01-07 KR KR1020177025584A patent/KR101966576B1/ko active IP Right Grant
- 2016-01-07 CN CN201680015614.4A patent/CN107406434B/zh not_active Expired - Fee Related
- 2016-01-07 TR TR2019/09997T patent/TR201909997T4/tr unknown
- 2016-01-07 CA CA2975973A patent/CA2975973C/en not_active Expired - Fee Related
- 2016-01-07 BR BR112017017275A patent/BR112017017275A2/pt not_active IP Right Cessation
- 2016-01-07 RS RS20190836A patent/RS59066B1/sr unknown
- 2016-01-07 EA EA201791829A patent/EA034618B1/ru unknown
- 2016-01-07 EP EP16711355.4A patent/EP3265459B1/en active Active
- 2016-01-07 PT PT16711355T patent/PT3265459T/pt unknown
- 2016-01-07 LT LTEP16711355.4T patent/LT3265459T/lt unknown
- 2016-01-07 NZ NZ734400A patent/NZ734400A/en not_active IP Right Cessation
- 2016-01-07 ES ES16711355T patent/ES2734734T3/es active Active
- 2016-01-07 DK DK16711355.4T patent/DK3265459T3/da active
- 2016-01-07 PL PL16711355T patent/PL3265459T3/pl unknown
- 2016-01-07 MX MX2017010348A patent/MX368214B/es active IP Right Grant
- 2016-01-07 ME MEP-2019-190A patent/ME03430B/me unknown
- 2016-01-07 JP JP2017542107A patent/JP6487564B2/ja not_active Expired - Fee Related
-
2017
- 2017-08-04 ZA ZA2017/05292A patent/ZA201705292B/en unknown
- 2017-08-06 IL IL253848A patent/IL253848B/en active IP Right Grant
-
2019
- 2019-07-01 HR HRP20191179TT patent/HRP20191179T1/hr unknown
- 2019-07-10 CY CY20191100739T patent/CY1121898T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL248347A0 (en) | Compounds and preparations as agonists of toll-like receptor 7 | |
| IL248311A0 (en) | Compounds and preparations as agonists of toll-like receptor 7 | |
| HK1255163A1 (zh) | 作為apj受體激動劑的雜芳基羥基嘧啶酮 | |
| GB201514875D0 (en) | Receptor | |
| HK1252163A1 (zh) | 受體 | |
| ZA201604527B (en) | Compounds for use as gpr120 agonists | |
| IL253848A0 (en) | Amine compounds as 5-hydroxytryptamine 4 receptor agonists | |
| HK1246184A1 (zh) | 作為a7-烟碱乙酰膽碱受體激動劑的氨基苯並惡唑化合物 | |
| IL251029A0 (en) | Heterocyclic compounds have been identified as gpr120 agonists | |
| IL247143A0 (en) | A new use of agonistic compounds for the sigma-1 receptor | |
| IL245948B (en) | 5–ht4 indazole compounds as receptor agonists | |
| HK1231414A1 (zh) | 胃輕癱用 受體激動劑 | |
| GB201619637D0 (en) | C3a receptor agonists | |
| PT3247719T (pt) | Proteínas agonistas do receptor met | |
| GB201500297D0 (en) | Agonists | |
| AU361570S (en) | Trough | |
| GB201419433D0 (en) | Dopamine D3 receptor antagonist compounds | |
| GB201419430D0 (en) | Dopamine D3 receptor antagonist compounds |